The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.The P/E ratio of Esperion Therapeutics is -4.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Get daily stock ideas top-performing Wall Street analysts.
View our full suite of financial calendars and market data tables, all for free.Shares of ESPR can be purchased through any online brokerage account. All rights reserved. Get short term trading ideas from the MarketBeat Idea Engine. Data may be intentionally delayed pursuant to supplier requirements. The Company produces oral and small molecule therapies for the treatment of patients with elevated levels of low-density ...Any opinions, news, research, analyses, prices, or other information offered by AIStockFinder is provided as general market commentary, and does not constitute investment advice. View real-time stock prices and stock quotes for a full financial overview. View which stocks are hot on social media with MarketBeat's trending stocks report.Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.In the past three months, Esperion Therapeutics insiders have not sold or bought any company stock.Esperion Therapeutics has a market capitalization of $1.10 billion and generates $148.36 million in revenue each year. All Rights Reserved.There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...BRIEF-Esperion Reports Commercial Availability Of Nexlizet Tablets * ESPERION THERAPEUTICS INC - ANNOUNCES COMMERCIAL AVAILABILITY OF NEXLIZET TABLETS BRIEF-Esperion Announces Agreement With ...The book value per share is 6.56$A stock is considered to be oversold if the RSI reading falls below 30. All times are ET. See ESPR stock predictions by 5 financial experts and find out if their Esperion stock forecast (ESPR) is more bullish in comparison to other stocks in the Healthcare sector. All rights reserved. Esperion Therapeutics employs 76 workers across the globe.Identify stocks that meet your criteria using seven unique stock screeners. Esperion Therapeutics, Inc. Common Stock (ESPR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.You have already added five stocks to your watchlist. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. In the short term (2weeks), ESPR's stock price should outperform the market by 0.83%.During that period the price should oscillate between -10.67% and +12.93%.. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.Learn everything you need to know about successful options trading with this three-part video course.Esperion Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Esperion Therapeutics has received 56.41% “outperform” votes from our community. The average price target is $80.67 with a high forecast of $158.00 and a low forecast of $42.00. Factset: FactSet Research Systems Inc.2019. Find the latest Esperion Therapeutics, Inc. (ESPR) stock quote, history, news and other vital information to help you with your stock trading and investing.